Philips introduces a unique biosensor technology

Royal Philips Electronics has now developed a unique biosensor technology which has the potential to offer lab-quality immunoassay results at the point of care. The company unveiled its initiative to transform the rapid diagnosis sector of the in-vitro diagnostics market at Medica 2008, where the 40th World Forum for Medicine is taking place (Düsseldorf, Germany, November 19 – 22).

magnotech-technologyPhilips’ new Magnotech technology, which uses magnetic nanoparticles to measure target molecules, could bring complex in-vitro diagnostic tests out of the laboratory and into decentralized settings, including the patient’s bedside and at home. The potential speed, ease of use, robustness and accuracy of this new technology could address the requirements of critical care environments by speeding up the diagnosis of life-threatening diseases. In addition, it could be suitable for monitoring chronically ill patients at home.

“Magnotech opens the door for change. It may offer the IVD industry the option of moving some tests out of the lab,” explains Marcel van Kasteel, Vice President and Chief Executive Officer of Philips Handheld Immunoassays. “Long term, we envisage that different testing stations – both conventional, automated labs and these new, mobile handheld systems – will be part of a diagnostic network, using wired or wireless connectivity and sophisticated healthcare informatics solutions to store and assist in interpreting the data.”

Results from small sample volumes
Integrated into a disposable biosensor cartridge that inserts into a hand-held analyzer, Magnotech uses magnetic nanoparticles to measure target molecules in very low (picomolar) concentrations in blood or saliva – in just a few minutes. The disposable cartridge automatically fills itself from a single drop of blood or saliva. Once filled, no other fluid movement is required. Currently, measuring very low concentrations of biomarkers for the diagnosis of disease (for example, cardiovascular disease) requires laboratory analysis, large sample volumes and a time-to-result delay of between 30 and 60 minutes.

The Philips’ Magnotech handheld technology has the potential to deliver:

  • Small sample volume (fingerpick drop of blood or saliva)
  • Ease of use (potentially applicable for home testing)
  • Multi-analyte (several analytes can be measured simultaneously, depending on the application) Lab-quality sensitivity
  • Speed (measurement in 1-5 minutes depending on the application)
  • The underlying technology
    The magnetic nanoparticles are preloaded into the cartridge during its manufacture and automatically disperse into the sample as the cartridge fills with saliva or blood. Coated with appropriate ligand molecules, the nanoparticles quickly bind to target molecules in the fluid sample.

    An electromagnet situated under the cartridge brings the magnetic nanoparticles, including the captured target molecules, into contact with the active detection surface of the biosensor in order to achieve fast specific binding at this active surface. A second magnetic field then pulls any unbound magnetic nanoparticles away from the active surface, enabling measurement of the remaining target molecules. The measurement is done using an optical technique based on frustrated total internal reflection.

    Philips has demonstrated proof-of-concept for its new biosensor technology in a variety of biological assays, including sandwich assays for the detection of cardiac Troponin I (cTnI)[2] and parathyroid hormone (PTH)[1], and inhibition assays to detect several drugs-of-abuse molecules (amongst others, morphine). Cardiac Troponin is a blood-borne protein that at elevated levels provides a useful biomarker for the diagnosis of myocardial infarction (heart attack). The morphine assay represents the first test of the technology in drugs-of-abuse testing.

    During these proof-of-concept tests, Philips’ Magnotech technology was shown to speed up assays by a factor of more than 100 when compared to simply letting the nanoparticles diffuse to the sensor’s active surface. Furthermore, the technology improves ease of use by eliminating fluidic washing steps. With cTnI, the assay successfully detected minute (picomolar) concentrations in under five minutes.

    Royal Philips Electronics develops the goLITE BLU, advanced light therapy device

    Royal Philips Electronics (NYSE: PHG, AEX: PHI) has introduced the goLITE BLU, a natural, convenient way to offer quick relief from seasonal mood-related problems. With the end of Daylight Saving time many Americans are affected by the increased darkness and experience what is known as the winter blues. Symptoms of the winter blues may include lethargy, lowered mood, problems sleeping, carbohydrate cravings and weight gain.

    golite_blu_photo1_smallThe Philips goLITE BLU is a new therapy light designed as a safe, simple and effective solution to help beat the winter blues. In scientific research, light therapy has been shown to improve mood and energy by regulating our internal body clock or circadian rhythms – the body’s 24-hour cycle of activity and sleep related to light. According to Dan Adams, a research manager at Philips Home Healthcare Solutions, “The body clock is stimulated by blue light like the blue found in the summer sky. In the winter we get less of this light and so many people suffer from the winter blues. “

    Light therapy is a natural way of beating the winter blues without the use of drugs or artificial stimulants. Results can be felt within a few days with as little 15 to 20 minutes of use per day. “The goLITE BLU represents significant improvements in portable blue light therapy,” says Adams. “Science has shown that to stimulate the body clock we don’t need intense white light. This is because a person’s body clock can respond up to two times greater to blue light than to white light and white light is 50 times more intense. Our Bluewave technology, which is incorporated into the goLITE BLU, dramatically reduces the overall intensity of light as compared to bright white therapy devices and can help minimize potential side effects such as eyestrain, glare and headaches.”

    The new goLITE BLU has been enhanced with innovative aesthetics and advanced features to provide a comfortable user experience. Features include:

  • A soft, even, comfortable light that helps to eliminate the harsh glare and contrast problems associated with traditional light therapy products.
  • A wide viewing field to enable the user to perform routine activities such as reading, eating, watching television or computer work while using the device.
  • A sleek design that makes the device easy to use, pack and store. It also fits in nicely with any room or office décor.
  • Backlit touch screen controls that are simple to use and program.
  • The stylish device, which measures 5.3” x 5.5” and weighs only 12 ounces, is equipped with a built-in clock and timer, rechargeable battery and protective storage case for convenient transport from home to office or while traveling. Designed to be safe and easy to use, the goLITE BLU passes ocular safety testing and all government and industrial ocular safety standards. It does not emit any harmful ultraviolet (UV) or near-UV light.

    The benefits of light therapy can include improved mood, energy, sleep and a sense of relief from the winter blues. Light therapy can also be used by shift workers or those who travel across time zones and have issues pertaining to jet lag.

    Price
    The suggested retail price for the goLITE BLU is $279.

    Philips announced the launch of its advanced handheld ultrasound system, the Philips CX50 CompactXtreme

    Andover, Mass. United States – Royal Philips Electronics (NYSE: PHG; AEX: PHI) today announced the launch of its advanced handheld ultrasound system, the Philips CX50 CompactXtreme. Designed to meet the needs of cardiologists for clear diagnostic data at the bedside, the new compact system combines the image quality expected of a traditional, premium, full-size system with the convenience of portability.

    “Following extensive research into clinicians’ needs, we’ve designed a laptop-sized system that can help them get to patients quickly—no matter where they are in the hospital or clinic—and which can produce high quality images regardless of the difficulty of the situation at hand,” said Anne LeGrand, senior vice president and general manager, Ultrasound, for Philips Healthcare.

    “Clinicians told us that small, portable systems are beneficial, as long as the image quality can help them make a confident diagnosis. If poor image quality from a handheld system results in inconclusive data, repeat exams may be needed at the cost of additional time and money. The CX50 was designed to consistently deliver high-quality images, even in technically challenging patients.”

    The CX50 CompactXtreme, which was first showcased during Philips’ recent analyst day on May 16, features Philips breakthrough PureWave transducer, which is clinically proven to improve penetration in difficult-to-image patients and to reduce clutter so clinicians can view fine structures in excellent detail. It also features Philips XRES adaptive image processing for reduced speckle and haze inherent with ultrasound imaging. As a result, images are virtually free from noise and have extraordinary clarity and edge definition.

    “Philips CX50 CompactXtreme system is truly the most advanced ultrasound system available today because its excellent image quality allows us to diagnose our patients quickly and confidently at the bedside,” said Thomas Buck, MD, Associate Professor of Medicine, University of Essen, West German Heart Center, Gesamthochschule, Germany. “The combination of PureWave technology and XRES processing enables the system to deliver the same image quality as full-size systems, allowing full echo data analysis from a portable system without any compromises.”

    The CX50 CompactXtreme offers portability to address multiple scanning environments. Its built-in handle and battery allow users to pickup-and-go for quick responses. For added convenience, it has a cart designed specifically for the system for effortless maneuvering throughout the hospital. And a wheeled case supports easy travel to remote locations. The system features Philips intuitive user interface, iSCAN automatic optimization and on-cart quantification software (QLAB) to maximize ease of use for clinicians.

    The newly launched Philips CX50 CompactXtreme supports adult transthoracic and transesophageal cardiology applications.

    Philips announced the latest addition to its HD15 ultrasound system

    Andover, Mass., USA – Royal Philips Electronics (NYSE: PHG, AEX: PHI) today announced the latest addition to its HD ultrasound family of products. The Philips HD15 ultrasound system provides physicians with superb imaging and workflow performance in a cost-effective system.

    The HD15 is a new platform designed to deliver an advanced level of image clarity and broad application support for everyday use in small hospitals, clinics and private practices. The system may be used as a primary system for some users, particularly those in emerging markets who require a feature-rich system but may not need all of the features of a high-end ultrasound solution. The HD15 contains multiple usability features to improve workflow, as well as versatile capabilities for a wide range of exam types including general imaging, cardiac, vascular and OB/GYN applications. In addition, advanced features like contrast enhanced ultrasound and PureWave transducer technology allow users to perform real-time guidance and evaluation of minimally-invasive treatment procedures and provide more diagnostic confidence on technically challenging patients and pathologies.

    “Physicians are increasingly turning to ultrasound to help support the growing demand for diagnostic exams and treatment guidance,” said Anne LeGrand, senior vice president, Ultrasound, for Philips Healthcare. “The HD15 brings capabilities that assure user simplicity and productivity to more clinicians, in a variety of clinical settings worldwide.”

    Advanced Philips technologies such as QLAB quantification software, XRES image processing and PureWave transducer crystal technology have been integrated into the HD15 to provide clinicians a robust system that assures ease of use and productivity. New Microfine EX focusing provides sharper images and improved tissue uniformity throughout the depth of field through application of new dynamic receive lens tuning with five times more focal points than previous generation systems. Tissue Specific Imaging presets and iSCAN one button image optimization can quickly provide clear images with little to no adjustment. A broad suite of configurable patient reports and exam storage options, such as DVD-CD-R/RW, USB drive, and full DICOM capabilities, provide efficient patient data management and colleague or specialist consulting.

    The HD15 may potentially change the way clinicians review ultrasound exams with active native data and live compare. Active native data allows clinicians to manipulate exam parameters and image settings even after the patient has left. Images and Cineloops can receive further investigation by manipulating the original image to see new detail. Live compare allows the clinician to compare a previous exam side-by-side with an active exam in order to immediately see changes in structure or blood flow. This can be particularly helpful in comparing changes in cardiac and vascular anomalies, further documenting changes after interventional procedures, or evaluating fetal development.

    The HD family of performance systems now includes the small, utilitarian HD3, the HD7 which was introduced earlier this year, the popular, feature-rich HD11 XE and the new HD15. More information on the Philips HD15 ultrasound system is available at: www.philips.com/HD15

    Philips introduces its first patient monitoring system 'designed for emerging markets' in India

    Wednesday, July 16, 2008
    * Targets a market share of 40% by 2010 in the Indian patient monitoring equipment market
    * Compact, high tech, full featured monitors suitable for use in a variety of care settings, including Hospitals, Nursing homes, Day Care Centres or Outpatient clinics in metros as well as sub urban & rural areas

    Hyderabad, India – Royal Philips Electronics (NYSE: PHG, AEX: PHI) today announced a series of new portable, compact patient monitors that provides a reliable, yet affordable means to observe and care for patients. Now available to healthcare providers in India, the new Philips SureSigns VM3 is the first Philips patient monitor designed for emerging markets.

    With a growing per capita income and adoption of new lifestyles, healthcare services in India are rapidly changing. In order to meet the increasing demand for quality care, people in urban areas have seen the construction of new, state-of-the-art hospitals and associated satellite facilities, while others are increasingly seeking care at smaller nursing homes and clinics. This has fueled the demand for healthcare equipment across segments and the growth of the Indian patient monitoring equipment market is estimated to reach USD 42 million in 2010. Philips plans to garner a market share of 40% by 2010 through its diverse range of patient monitoring equipment.

    “The SureSigns VM3 leverages the high-quality platform of Philips’ industry leading patient monitoring portfolio,” said Anjan Bose, senior director and business head, India, Bangladesh, Sri Lanka and Nepal, Philips Healthcare India. “Combining advanced software and technology in a compact economical package, the VM3 is the perfect solution for caregivers across the wide variety of clinical environments we see here in India. This launch reaffirms our commitment to the Indian market, leveraging Philips’ global expertise to introduce technologically-advanced offerings tailored to this market.”

    High-end patient monitors are out of reach for many small to mid-sized clinics, forcing doctors and nurses to apply treatment only based on visible symptoms. On occasion, this means they must wait for a patient’s condition to deteriorate before changing treatment. With access to more affordable patient monitoring equipment, clinicians have the ability to observe a patient’s vital signs and make more informed, timely decisions about patient care.

    Built on a strong heritage and industry leadership in patient monitoring, the Philips SureSigns VM3 offers ECG, respiration and pulse oximetry in one user friendly, compact monitor that helps provide quality care in almost any clinical setting. It offers vital signs measurement and monitoring in an easy-to-use system that can be used in various departments throughout the hospital, nursing homes, private practices and rural clinics, as well as ambulances and mobile facilities.

    “Philips is known globally for its cutting edge monitoring technology, and the strong after sales support with back-up in India, have made us active users of SureSigns Monitors. Further the monitoring parameters of SureSigns closely relate to the clinical findings, and that speaks highly for the algorithms devised and designed by Philips Healthcare,” said Dr. Chandrasekhar, Head Of Department, Anesthesia, Osmania General Hospital, Hyderabad.

    Like all other Philips SureSigns products, the VM3 is easy to set up, learn, use, and support, with intuitive navigation and color displays that are bright and easy to read, even in low-light situations. In addition, Philips also launched the SureSigns Vital Signs Viewer (VSV) to complement their entire VM-series patient monitors.

    The VSV is an affordable, reliable, and simple way to provide the benefits of central viewing and alarming without the complexity and expense of a traditional PC-based central station. Central viewing and alarming can benefit any care area with a high patient-to-caregiver ratio. Having a clear picture of each patient’s status, at a single glance, helps improve patient care and helps relieve stress on nursing staff.

    The VSV displays vital signs data and one waveform from up to 12 patient monitors at a time. In fact, with the VSV, customers can add central monitoring for a department for about the cost of a single VM Series monitor.

    Philips is a leading supplier of patient monitoring equipment with 38% market-share in 2007 and having installations across India in leading hospitals as well as remote areas. Philips has introduced several new Patient monitoring products in the last six months to further expand its presence in India. These include IntelliVue MP2, IntelliVue X2, IntelliVue MP5, SureSigns series and Avalon FM20 Fetal monitors.

    Philips to transfer its PC monitors business to TPV Technology

    Tuesday, July 08, 2008

    Amsterdam, The Netherlands – Royal Philips Electronics (NYSE:PHG, AEX:PHI) today announced that it has reached an agreement with TPV Technology Limited. (SEHK: 903) on key terms and conditions of a brand licensing agreement under which Philips will transfer its PC monitors business, IT Displays, to TPV. This is in line with Philips’ previously communicated commitment to take decisive steps to improve the profitability levels at its Television business, of which the IT Displays unit forms part.

    Under the terms of this agreement, TPV, the largest producer of PC monitors worldwide, will assume responsibility for sourcing, distribution, marketing and sales of all Philips’ IT Displays activities worldwide. As part of the intended brand licensing agreement, TPV can exclusively use the Philips brand name for PC monitors worldwide, in exchange for which Philips will receive revenue-based royalty payments. Philips IT Displays sales amounted to approximately EUR 600 million in 2007. Completion of this intended transaction, which is expected in the course of 2008, is subject to applicable regulatory approvals and the fulfillment of specific closing conditions.

    The intended agreement with TPV represents a further step by Philips to fundamentally reposition itself in the digital display business and accelerates Philips’ efforts to address the unsatisfactory performance of its television business. In April of this year, Philips already announced it would transfer its consumer television operations in North America, while at the same time it said it would take steps to further optimize its global supply base in TV. Philips remains ahead-of-plan in optimizing its TV operations and will book approximately EUR 66 million in charges in the second quarter of 2008, which are largely related to these efforts.

    Philips to buy out 3.5% from shareholders

    Kolkata, Jun 13 Philips Electronics India Ltd, the health care and well being product company, has decided to buy out 3.5% of the minority share holding by paying Rs 260 per share, well above the previous open offer of Rs 135 per share, in 2003.

    Philips will pay a total amount of Rs 180 crore for 6,923,076 shares, which is 9.9% of the total equity.

    The buy-back offer will also provide an opportunity for the promoter of the company, Koninklijke Philips Electronics NV, which holds 96.5% to have a proportional share in the buy-back scheme–not more than 9.5% of the issued share of the capital.

    For the promoters, the gain will be maximum of Rs 160 crore if none of the minority share holders exercises his/her rights. In that case, promoters holding will come down by a few points. In the 78 th annual general meeting one of the resolutions was the buy-back proposal.

    First HDMI Authorized Testing Centre

    Royal Philips Electronics has inaugurated India’s first High Definition Multimedia Interface (HDMI) Authorized Testing Centre (ATC) laboratory in its Bangalore-based Philips Innovation Campus. The test centre will facilitate HDMI compliance testing services as per HDMI Compliance Test Specification (CTS) 1.3b. The centre is Philips’ only HDMI ATC globally and the eighth HDMI ATC to be opened worldwide.

    Philips has increased the global testing capacity for HDMI-compliant solutions with the inauguration of this testing facility in India. This facility will help meet market demand for HDMI technology adhered to compliance and drive interoperability with other HDMI devices.

    With over 800 companies adopting HDMI as a standard for their products globally, the market holds huge potential for the technology standard. Globally, over 200 million devices featuring HDMI are expected to ship in 2008, with an installed base of nearly one billion HDMI devices by 2010.

    Philips ATC is equipped to perform all of the testing as mandated in HDMI CTS1.3b, including High-bandwidth Digital Content Protection (HDCP) Compliance testing and HDMI CEC (Consumer Electronic Control) testing. The HDMI consortium mandates that a product should pass compliance testing at an ATC before it can bear the logo of HDMI and claim conformance to the HDMI specification

    Asustek Reduces Notebook Shipment Forecast

    TAIPEI – Asustek Computer Inc. reduced its global notebook PC shipment forecast to 6.6 million units for 2008, down from a projected 7 million units, say published reports.

    The firm’s original projection was up more than 60% compared to 2007 results. However, the company adjusted the forecast downward by 5.7%.

    Asustek attributes the adjustment to strong market competition; the European market is particularly struggling, with the second-quarter growth rate estimated at a mere 3 to 5%.

    The firm forecasts sales of its Eee PC to reach 5 million units globally in 2008, including 1.3 million units in the second quarter.

    Philips agrees to sell MedQuist stake to CBay Systems

    Philips agrees to sell MedQuist stake to CBay Systems

    Thursday, May 22, 2008 : Amsterdam, the Netherlands and London, the United Kingdom – Royal Philips Electronics (AEX: PHI, NYSE: PHG) (“Philips”) today announced it has reached an agreement to sell its approximate 69.5% ownership interest in MedQuist Inc. (Pink Sheets: MEDQ.PK) to CBay Systems Holdings (AIM: CBAY) (“CBay”) for USD 11.00 per share, or approximately USD 285 million (approximately EUR 185 million). The USD 11.00 per share purchase price represents a premium of 47% over the most recent trading price of MedQuist’s stock. The acquisition of the approximate 69.5% shareholding in MedQuist will complement CBay Systems Holdings’ existing portfolio of businesses in medical transcription, healthcare technology, and healthcare financial services, including CBay Systems & Services Inc, CBay Systems Private Ltd. and Mirrus Systems.

    The sale of Philips’ stake in MedQuist is expected to close during the third quarter of 2008, and is conditional upon applicable regulatory approvals, approval by CBay shareholders at a general meeting of shareholders, and the fulfillment of specific closing conditions. In connection with this transaction, Philips will receive cash and a promissory note equivalent to approximately USD 7.50 per share, amounting to approximately USD 195 million (approximately EUR 125 million). The remaining per share consideration of approximately USD 3.50 per share will be paid to Philips in the form of a 7-year bond convertible into common stock of CBay. The financial results related to this transaction, which are expected to be immaterial, will be booked under “Discontinued Operations” in Philips’ third quarter 2008 results.

    Today’s announcement follows a November 2, 2007 announcement, in which Philips indicated its intention to proceed with the sale of its approximate 69.5% ownership interest, as well as a July 6, 2007 announcement, in which Philips indicated it viewed its stake in MedQuist as a non-core holding.

    For more information, please contact:
    Jayson Otke
    Philips Corporate Communications
    Tel: +31 20 5977215
    Email: jayson.otke@philips.com

    David Wolf
    Philips Corporate Communications North America
    Tel: +1 917 455 7857
    Email: david.l.wolf@philips.com

    Mark Court
    For CBay Systems Holdings Ltd.
    Buchanan Communications
    Tel: + 44 (0) 2…
    Email: markc@buchanan.uk.com

    Next Page »